Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques [PublishAheadOfPrint]

A nanoformulated myristoylated dolutegravir prodrug (NMDTG) was prepared using Good Laboratory Practice protocols. Intramuscular injection of NMDTG (118 ± 8 mg/ml, 25.5 mg DTG equivalents/kg) to three rhesus macaques led to plasma DTG levels of 86 ± 12 and 28 ± 1 ng/ml on days 35 and 91, respectively. The NMDTG platform extended the drug half-life without demonstrable adverse events. Further modification may extend the long-acting nanoformulation platform for human use.

http://ift.tt/2yJtKIw